研究人员正在开发LASSARAB疫苗候选剂,用于拉萨热,临床前成功,正在进行第1期试验. Researchers develop LASSARAB vaccine candidate for Lassa fever with preclinical success, pending phase 1 trial.

Thomas Jefferson大学和马里兰大学的研究人员创造了一个新的疫苗候选者,LASSARAB,以防治拉萨热,这是西非流行的一种严重疾病,死亡率很高。 Researchers from Thomas Jefferson University and the University of Maryland have created a new vaccine candidate, LASSARAB, to combat Lassa fever, a severe disease endemic to West Africa with significant mortality rates. 在临床前研究中,LASSARAB有效预防了严重病例,并使用了停用的狂犬病病毒平台,为这两种病毒提供了双重保护。 In preclinical studies, LASSARAB effectively prevented severe cases and utilized a deactivated rabies virus platform, providing dual protection against both viruses. 经林业发展局批准,第一阶段临床试验定于11月进行。 A phase 1 clinical trial is slated for November, following FDA approval.